Metabolic Partnering Terms and Agreements

Introduction

Abstract

Description

The Metabolic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter metabolic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors metabolic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual metabolic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in metabolic dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading metabolic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of metabolic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all metabolic deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all metabolic partnering deals signed and announced since 2007. The chapter is organized by specific metabolic therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all metabolic partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in metabolic partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of metabolic technologies and products.

Benefits

Metabolic Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of metabolic deal trends since 2007
• Access metabolic deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between metabolic partner companies
• Comprehensive access to over 1,000 links to actual metabolic deals entered into by the world's biopharma companies
• Indepth review of metabolic deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner metabolic opportunities
• Uncover companies actively partnering metabolic opportunities

Table of Contents

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

• 2.1. Introduction
• 2.2. Metabolic partnering over the years
• 2.3. Bigpharma metabolic dealmaking activity
• 2.4. Bigpharma not active in metabolic
• 2.5. Metabolic partnering by deal type
• 2.6. Metabolic partnering by industry sector
• 2.7. Metabolic partnering by stage of development
• 2.8. Metabolic partnering by technology type
• 2.9. Metabolic partnering by metabolic indication
• 2.10. Average deal terms for metabolic diseases
  • 2.10.1 Metabolic headline values
  • 2.10.2 Metabolic upfront payments
  • 2.10.3 Metabolic milestone payments
  • 2.10.4 Metabolic royalty rates

Chapter 3 - Leading metabolic deals

• 3.1. Introduction
• 3.2. Top metabolic deals by value
• 3.3. Top metabolic deals involving bigpharma

Chapter 4 - Bigpharma metabolic deals

• 4.1. Introduction
• 4.2. How to use bigpharma partnering deals
• 4.3. Bigpharma metabolic partnering company profiles
  • Abbott
  • Actavis
  • Allergan
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merck Serono
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Pfizer Animal Health
  • Pfizer Nutrition
  • Roche
  • Sanofi
  • Servier
  • Shire
  • Takeda
  • Teva
  • Valeant
  • Watson

Chapter 5 - Metabolic partnering contracts directory

• 5.1. Introduction
• 5.2. By deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Licensing
  • Litigation
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
• 5.3. By stage of development
  • Discovery
  • Formulation
  • Marketed
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Regulatory
  • Formulation
• 5.4. By technology type
  • Analysis
  • Animal models
  • Assays
  • Biological compounds
  • Biomarkers
  • Biomaterials
  • Blood products
  • Cell culture
  • Cell therapy
  • Clinical testing
  • Devices
  • Diagnostics
  • Discovery tools
  • Drug delivery
  • Enabling technology
  • Facilities
  • Gene therapy
  • Genomics
  • Imaging
  • Implant
  • In vitro models
  • Nanotechnology
  • Natural product
  • Oligonucleotide
  • Orphan drug
  • Packaging
  • Peptides
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Regenerative medicine
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Toxicity
  • Vaccines

Chapter 6 - Metabolic dealmaking by indication

• 6.1. Introduction
• 6.2. Deals by therapeutic indication
  • Metabolic
  • Acromegaly
  • Addison's disease
  • Cirrhosis
  • Cushing's syndrome
  • Diabetes
  • Fatty liver
  • Gallstones
  • Growth hormone disorders
  • Hyperthyroidism
  • Hypogonadism
  • Hypothyroidism
  • Phenylketonuria
  • Liver disease
  • Lysosomal storage disorders
  • Nutrition and vitamins
  • Short stature
  • Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
  • Thyroid disease

Chapter 7 - Partnering resource center

• 7.1. Online partnering
• 7.2. Partnering events
• 7.3. Further reading on dealmaking
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Therapy Reports

Appendices

• Appendix 1 - Directory of metabolic deals by company A-Z 2007-2012
• Appendix 2 - Directory of metabolic deals by deal type 2007-2012
• Appendix 3 - Directory of metabolic deals by stage of development 2007-2012
• Appendix 4 - Directory of metabolic deals by technology type 2007-2012
• Appendix 5 - Deal type definitions

Table of figures

• Figure 1: Metabolic partnering since 2007
• Figure 2: Bigpharma - top 50 - metabolic deals 2007 to 2012
• Figure 3: Bigpharma metabolic deal frequency - 2007 to 2012
• Figure 4: Inactive bigpharma in metabolic 2007-2012
• Figure 5: Metabolic partnering by deal type since 2007
• Figure 6: Metabolic partnering by industry sector since 2007
• Figure 7: Metabolic partnering by stage of development since 2007
• Figure 8: Metabolic partnering by technology type since 2007
• Figure 9: Metabolic partnering by metabolic target since 2007
• Figure 10: Metabolic deals with a headline value
• Figure 11: Metabolic deal headline value distribution, US$million - discovery stage
• Figure 12: Metabolic deal headline value distribution, US$million - preclinical stage
• Figure 13: Metabolic deal headline value distribution, US$million - phase I stage
• Figure 14: Metabolic deal headline value distribution, US$million - phase II stage
• Figure 15: Metabolic deal headline value distribution, US$million - phase III stage
• Figure 16: Metabolic deal headline value distribution, US$million - regulatory stage
• Figure 17: Metabolic deal headline value distribution, US$million - marketed stage
• Figure 18: Summary median headline value by stage of development, 2007-2012
• Figure 19 Metabolic deals with upfront payment values
• Figure 20: Metabolic deal upfront payment distribution, US$million - discovery stage
• Figure 21: Metabolic deal upfront payment distribution, US$million - preclinical stage
• Figure 22: Metabolic deal upfront payment distribution, US$million - phase I stage
• Figure 23: Metabolic deal upfront payment distribution, US$million - phase II stage
• Figure 24: Metabolic deal upfront payment distribution, US$million - phase III stage
• Figure 25: Metabolic deal upfront payment distribution, US$million - regulatory stage
• Figure 26: Metabolic deal upfront payment distribution, US$million - marketed stage
• Figure 27: Summary median upfront payments by stage of development, 2007-2012
• Figure 28: Metabolic deals with milestone payments
• Figure 29: Metabolic deal milestone distribution, US$million - discovery stage
• Figure 30: Metabolic deal milestone distribution, US$million - preclinical stage
• Figure 31: Metabolic deal milestone distribution, US$million - phase I stage
• Figure 32: Metabolic deal milestone distribution, US$million - phase II stage
• Figure 33: Metabolic deal milestone distribution, US$million - phase III stage
• Figure 34: Metabolic deal milestone distribution, US$million - regulatory stage
• Figure 35: Metabolic deal milestone distribution, US$million - marketed stage
• Figure 36: Metabolic deals with royalty rates, %
• Figure 37: Metabolic deal royalty rate distribution, US$million - discovery stage
• Figure 38: Metabolic deal royalty rate distribution, US$million - preclinical stage
• Figure 39: Metabolic deal royalty rate distribution, US$million - phase I stage
• Figure 40: Metabolic deal royalty rate distribution, US$million - phase II stage
• Figure 41: Metabolic deal royalty rate distribution, US$million - phase III stage
• Figure 42: Metabolic deal royalty rate distribution, US$million - regulatory stage
• Figure 44: Summary median royalty rate by stage of development, 2007-2012
• Figure 45: Top metabolic deals by value since 2007
• Figure 46: Top metabolic deals signed by bigpharma value since 2007
• Figure 47: Online partnering resources
• Figure 48: Forthcoming partnering events

Metabolic Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 448 Pages and the price starts from US $ 2695.

The contents of this page may be different from the latest version. Please contact us for details.